Publications by authors named "Eva Remenar"

Claim this Profile
E
EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.
Mihály Cserepes, Györgyi A Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With Mutation and Amplification Achieved by Dual Trametinib and Metformin Therapy.
Éva Remenár, Róbert Dóczi, Anna Dirner, Anna Sipos, Anita Perjési

JCO Precis Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Petr Szturz, Marie Vinches, Éva Remenár, Carla M L van Herpen, Cyril Abdeddaim

Eur J Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC].
Mihály Cserepes, Györgyi A Nelhűbel, Mónika Meilinger-Dobra, Sára Eszter Surguta, Erzsébet Rásó

Magy Onkol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical importance of retropharyngeal lymph node metastases].
Mónika Révész, Ferenc Oberna, Éva Remenár, Zoltán Takácsi-Nagy

Orv Hetil· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Martin D Forster, Magnus T Dillon, Judit Kocsis, Éva Remenár, Gabor Pajkos

Eur J Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.
Andrea Ladányi, Bence Kapuvári, Eszter Papp, Erika Tóth, József Lövey

Head Neck· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L Siu, Caroline Even, Ricard Mesía, Eva Remenar, Amaury Daste

JAMA Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Dan P Zandberg, Alain P Algazi, Antonio Jimeno, James S Good, Jérôme Fayette, Eva Remenar

Eur J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Retrospective analysis of papillary thyroid microcarcinoma cases treated between 2001 and 2010 in the Hungarian National Institute of Oncology].
Mónika Meilinger-Dobra, Éva Remenár, Georgina Fröhlich, István Sinkovics, Ilona Péter

Magy Onkol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Role of MRI and CT in the evaluation of postirradiation status and complications in head and neck cancer].
Mária Gõdény, Éva Remenár, Zoltán Takácsi-Nagy, Klára Petri, Katalin Horváth

Magy Onkol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma].
Szabolcs Bellyei, Péter Bakó, Éva Orosz, Krisztián Molnár, Éva Remenár

Magy Onkol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.
Denis Soulières, Lisa Licitra, Ricard Mesía, Éva Remenár, Shau-Hsuan Li

Clin Cancer Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Denis Soulières, Sandrine Faivre, Ricard Mesía, Éva Remenár, Shau-Hsuan Li

Lancet Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis.
Mária Gődény, Zsolt Lengyel, Gábor Polony, Zoltán Takácsi Nagy, Gergely Léránt

Cancer Imaging· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Zoltán Takácsi-Nagy, Erika Hitre, Éva Remenár, Ferenc Oberna, Csaba Polgár

Strahlenther Onkol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Kevin Harrington, Alain Berrier, Martin Robinson, Eva Remenar, Martin Housset

Eur J Cancer· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].
Miklós Fülöp, Miklós Kásler, Eva Remenár, Zsolt Lengyel, Katalin Borbély

Magy Onkol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Cytogenetic and hormonal changes in head and neck squamous cell cancer patients: potential biomarkers for functional approaches in surgical oncology].
Eva Remenár

Magy Onkol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Jan B Vermorken, Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki

N Engl J Med· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Applicable methods of reconstruction for the replacement of soft tissue after the radical resection of oral tumors].
Miklós Fülöp, András Boér, Eva Remenár, Csongor Lengyel, Miklós Kásler

Magy Onkol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Our clinical experience with fibula free flap].
Miklós Kásler, Eva Remenár, András Boér, Emoke Iványi, Miklós Fülöp

Magy Onkol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Phoniatrics in the rehabilitation for head and neck cancer].
Krisztina Mészáros, Eva Remenár, Miklós Kásler

Magy Onkol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Problems occurring in the application of cytogenetic biomarkers for alcoholics with and without malignant diseases].
Sarolta Gundy, Gábor Székely, Gyöngyi Farkas, Attila Pulay, Eva Remenár

Magy Onkol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Laser surgery of head and neck lesions at the National Institute of Oncology, Budapest].
Miklós Kásler, Eva Remenár, Csongor György Lengyel, András Boér

Magy Onkol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis